Pramipexole Teva

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
23-11-2021
Ciri produk Ciri produk (SPC)
23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
21-07-2013

Bahan aktif:

pramipexole dihydrochloride monohydrate

Boleh didapati daripada:

Teva Pharma B.V.

Kod ATC:

N04BC05

INN (Nama Antarabangsa):

pramipexole

Kumpulan terapeutik:

Anti-Parkinson drugs

Kawasan terapeutik:

Parkinson Disease

Tanda-tanda terapeutik:

Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

Ringkasan produk:

Revision: 22

Status kebenaran:

Authorised

Tarikh kebenaran:

2008-12-18

Risalah maklumat

                                43
B. PACKAGE LEAFLET
44
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRAMIPEXOLE TEVA 0.088 MG TABLETS
PRAMIPEXOLE TEVA 0.18 MG TABLETS
PRAMIPEXOLE TEVA 0.35 MG TABLETS
PRAMIPEXOLE TEVA 0.7 MG TABLETS
pramipexole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pramipexole Teva is and what it is used for
2.
What you need to know before you take Pramipexole Teva
3.
How to take Pramipexole Teva
4.
Possible side effects
5.
How to store Pramipexole Teva
6.
Contents of the pack and other information
1.
WHAT PRAMIPEXOLE TEVA IS AND WHAT IT IS USED FOR
Pramipexole Teva contains the active substance pramipexole and belongs
to a group of medicines
known as dopamine agonists,
_ _
which stimulate dopamine receptors in the brain. Stimulation of the
dopamine receptors triggers nerve impulses in the brain that help to
control body movements.
Pramipexole Teva is used to:
•
treat the symptoms of primary Parkinson’s disease in adults. It can
be used alone or in
combination with levodopa (another medicine for Parkinson’s
disease).
•
treat the symptoms of moderate to severe primary Restless Legs
Syndrome in adults.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRAMIPEXOLE TEVA
DO NOT TAKE PRAMIPEXOLE TEVA
•
if you are allergic to pramipexole or to any of the other ingredients
of this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor before taking Pramipexole Teva. Tell your doctor
if you have (had) or develop any
medical conditions or symptoms, especially any of the foll
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1. NAME OF THE MEDICINAL PRODUCT
Pramipexole Teva 0.088 mg tablets
Pramipexole Teva 0.18 mg tablets
Pramipexole Teva 0.35 mg tablets
Pramipexole Teva 0.7 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pramipexole Teva 0.088 mg tablets
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate
equivalent to 0.088 mg
pramipexole.
Pramipexole Teva 0.18 mg tablets
Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate
equivalent to 0.18 mg
pramipexole.
Pramipexole Teva 0.35 mg tablets
Each tablet contains 0.5 mg pramipexole dihydrochloride monohydrate
equivalent to 0.35 mg
pramipexole.
Pramipexole Teva 0.7 mg tablets
Each tablet contains 1.0 mg pramipexole dihydrochloride monohydrate
equivalent to 0.7 mg
pramipexole.
_Please note: _
Pramipexole doses as published in the literature refer to the salt
form.
Therefore, doses will be expressed in terms of both pramipexole base
and pramipexole salt (in
brackets).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pramipexole Teva 0.088 mg tablets
White, round, flat face bevel edge tablet, 5.55 mm diameter, embossed
with “93” on one side and “P1”
on the other side.
Pramipexole Teva 0.18 mg tablets
White, round, flat face bevel edge tablet, 7.00 mm diameter, embossed
with "P2" over "P2" on the
scored side and "93" on the other side. The tablet can be divided into
equal halves.
Pramipexole Teva 0.35 mg tablets
White to off-white, oval, biconvex tablets, engraved with 9 vertical
scoreline 3 on the scored side, and
8023 on the other side. The tablet can be divided into equal halves.
Pramipexole Teva 0.7 mg tablets
White, round, flat face bevel edge tablet, 8.82 mm diameter, embossed
with "8024" over "8024" on the
scored side and "93" on the other side. The tablet can be divided into
equal halves.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pramipexole Teva is indicated in adults for treatment of the signs and
symptoms of idiopathic
Parkinson’s disease
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 23-11-2021
Ciri produk Ciri produk Bulgaria 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 21-07-2013
Risalah maklumat Risalah maklumat Sepanyol 23-11-2021
Ciri produk Ciri produk Sepanyol 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 21-07-2013
Risalah maklumat Risalah maklumat Czech 23-11-2021
Ciri produk Ciri produk Czech 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 21-07-2013
Risalah maklumat Risalah maklumat Denmark 23-11-2021
Ciri produk Ciri produk Denmark 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 21-07-2013
Risalah maklumat Risalah maklumat Jerman 23-11-2021
Ciri produk Ciri produk Jerman 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 21-07-2013
Risalah maklumat Risalah maklumat Estonia 23-11-2021
Ciri produk Ciri produk Estonia 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 21-07-2013
Risalah maklumat Risalah maklumat Greek 23-11-2021
Ciri produk Ciri produk Greek 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 21-07-2013
Risalah maklumat Risalah maklumat Perancis 23-11-2021
Ciri produk Ciri produk Perancis 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 21-07-2013
Risalah maklumat Risalah maklumat Itali 23-11-2021
Ciri produk Ciri produk Itali 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 21-07-2013
Risalah maklumat Risalah maklumat Latvia 23-11-2021
Ciri produk Ciri produk Latvia 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 21-07-2013
Risalah maklumat Risalah maklumat Lithuania 23-11-2021
Ciri produk Ciri produk Lithuania 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 21-07-2013
Risalah maklumat Risalah maklumat Hungary 23-11-2021
Ciri produk Ciri produk Hungary 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 21-07-2013
Risalah maklumat Risalah maklumat Malta 23-11-2021
Ciri produk Ciri produk Malta 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 21-07-2013
Risalah maklumat Risalah maklumat Belanda 23-11-2021
Ciri produk Ciri produk Belanda 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 21-07-2013
Risalah maklumat Risalah maklumat Poland 23-11-2021
Ciri produk Ciri produk Poland 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 21-07-2013
Risalah maklumat Risalah maklumat Portugis 23-11-2021
Ciri produk Ciri produk Portugis 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 21-07-2013
Risalah maklumat Risalah maklumat Romania 23-11-2021
Ciri produk Ciri produk Romania 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 21-07-2013
Risalah maklumat Risalah maklumat Slovak 23-11-2021
Ciri produk Ciri produk Slovak 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 21-07-2013
Risalah maklumat Risalah maklumat Slovenia 23-11-2021
Ciri produk Ciri produk Slovenia 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 21-07-2013
Risalah maklumat Risalah maklumat Finland 23-11-2021
Ciri produk Ciri produk Finland 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 21-07-2013
Risalah maklumat Risalah maklumat Sweden 23-11-2021
Ciri produk Ciri produk Sweden 23-11-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 21-07-2013
Risalah maklumat Risalah maklumat Norway 23-11-2021
Ciri produk Ciri produk Norway 23-11-2021
Risalah maklumat Risalah maklumat Iceland 23-11-2021
Ciri produk Ciri produk Iceland 23-11-2021
Risalah maklumat Risalah maklumat Croat 23-11-2021
Ciri produk Ciri produk Croat 23-11-2021

Cari amaran yang berkaitan dengan produk ini